Adum Bio

Adum Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of novel small molecule drugs for oncology and autoimmune disorders. The company's primary focus is on next-generation cyclin-dependent kinase (CDK) inhibitors, specifically targeting CDK4/6 and CDK2 to address resistance mechanisms in various cancers. Its lead program, ADM-101, is a highly selective CDK4/6 inhibitor currently in clinical trials for advanced breast cancer and other solid tumors. Beyond its lead asset, the company is advancing ADM-201, a multi-CDK inhibitor, and ADM-301, a selective CDK2 inhibitor, to provide comprehensive solutions for cell cycle-driven malignancies. Adum Biopharma leverages its internal R&D capabilities and a team of experienced industry veterans to advance a pipeline of precision medicines aimed at addressing significant unmet medical needs.